Skip to main content

Drug Interactions between Braftovi and mavacamten

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

encorafenib mavacamten

Applies to: Braftovi (encorafenib) and mavacamten

Consumer information for this interaction is not currently available.

CONTRAINDICATED: Coadministration with moderate to potent inducers of CYP450 2C19 and/or CYP450 3A4 may significantly decrease the plasma concentrations and therapeutic efficacy of mavacamten. According to the prescribing information, mavacamten is primarily metabolized by CYP450 2C19 (74%) and to a lesser extent by CYP450 3A4 (18%) and 2C9 (8%). Concomitant use of a single dose of mavacamten (15 mg) with the potent CYP450 2C19 and 3A4 inducer rifampin (600 mg once daily) is predicted to decrease mavacamten peak plasma concentration (Cmax) and systemic exposure (AUC) by 22% and 87%, respectively, in CYP450 2C19 normal metabolizers, and by 4% and 69%, respectively, in CYP450 2C19 poor metabolizers. Because mavacamten reduces systolic contraction and left ventricular ejection fraction, the risk of heart failure due to systolic dysfunction may increase following discontinuation of CYP450 inducers like rifampin as the levels of induced enzymes normalize.

MANAGEMENT: Concomitant use of mavacamten with moderate to potent inducers of CYP450 2C19 and/or CYP450 3A4 is considered contraindicated.

References

  1. (2022) "Product Information. Camzyos (mavacamten)." MyoKardia Inc
  2. (2023) "Product Information. Camzyos (mavacamten)." Bristol-Myers Squibb Australia Pty Ltd, 2

Drug and food interactions

Major

encorafenib food

Applies to: Braftovi (encorafenib)

You should preferably avoid consumption of grapefruit and grapefruit juice while taking encorafenib. Grapefruit and grapefruit juice can significantly increase the blood levels of encorafenib. This may increase the risk of serious side effects such as bleeding complications, eye and vision problems, liver problems, irregular heart rhythm, and development of new skin cancers. Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Major

mavacamten food

Applies to: mavacamten

Grapefruit juice may increase the blood levels of mavacamten and increase the risk of heart failure, a condition where the heart is unable to pump blood adequately to meet the body's needs. Your risk may be further increased if you develop a serious infection or irregular heartbeat during treatment with mavacamten. You should avoid the consumption of grapefruit and grapefruit juice while taking this medication. Talk to your doctor if you have any questions or concerns. You should seek medical attention if you experience signs and symptoms of heart failure such as shortness of breath, chest pain, fatigue, swelling in your legs, palpitations, or rapid weight gain. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer